Salarius Pharmaceuticals, Inc. - SLRX STOCK NEWS

Salarius Pharmaceuticals (NASDAQ: SLRX) announced that Dr. Daniela Santiesteban will present at the 5th Annual Targeted Protein Degradation Conference on October 26 in Boston. Her presentation will cover the development of SP-3164, a molecular glue for cancer therapy, discussing its therapeutic benefits and data from cancer models. CEO David Arthur highlighted the importance of this conference for collaboration in targeted protein degradation. Salarius is advancing SP-3164, alongside its lead candidate, seclidemstat, which is in clinical trials for Ewing sarcoma and other cancers.

Salarius Pharmaceuticals (NASDAQ: SLRX) has announced a voluntary pause in new patient enrollment for its Phase 1/2 trial of seclidemstat, aimed at treating Ewing sarcoma and FET-rearranged sarcomas. This decision follows a suspected unexpected serious adverse reaction (SUSAR) related to a patient death. Current patients can continue treatment after consulting with their physicians. The company aims to analyze the data and resume enrollment promptly. Interim trial results are expected later this year, with a focus on improving outcomes for pediatric cancer patients.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced a 1-for-25 reverse stock split effective at 5:00 p.m. ET on October 14, 2022. Trading on a split-adjusted basis will start on October 17, 2022. This measure aims to regain compliance with the $1.00 minimum closing bid price for continued Nasdaq listing. Stockholder approval was granted in June 2022, leading to this decision. The number of shares will decrease from approximately 56.2 million to 2.2 million. Cash will be provided for any fractional shares.

HOUSTON, Sept. 20, 2022 – Salarius Pharmaceuticals (NASDAQ: SLRX) announced its participation in the 2022 Ladenburg Thalmann Healthcare Conference on September 29 in New York City. CEO David Arthur will deliver a corporate presentation and engage in a fireside chat at 10:30 a.m. Eastern Time. The event will be available via live webcast. Salarius develops innovative treatments for cancer, including its lead candidate, seclidemstat, currently in clinical trials for Ewing sarcoma. The company has received various FDA designations for this treatment.

Salarius Pharmaceuticals (NASDAQ: SLRX) recently provided an update on its developmental progress and future plans. The company’s lead candidate, seclidemstat, is advancing in a Phase 1/2 clinical trial for Ewing and related sarcomas, with interim data expected by year-end. Noteworthy is the expansion to 17 clinical sites, including prestigious institutions. Furthermore, the newly acquired SP-3164 is being developed as a targeted protein degrader. Salarius maintains strong financials with $22.6 million in cash, ensuring well-funded operations into 2023.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) has announced the expansion of its Phase 1/2 clinical trial for seclidemstat, a novel treatment for Ewing’s sarcoma and FET-rearranged sarcomas, to include two Mayo Clinic locations in Minnesota and Florida. This trial aims to explore seclidemstat's efficacy and safety in treating pediatric bone cancer and other related sarcomas. Interim data is expected in the second half of 2022, with hopes that seclidemstat will positively impact patient outcomes.

Salarius Pharmaceuticals (NASDAQ: SLRX) has expanded its ongoing Phase 1/2 clinical trial of seclidemstat for Ewing’s sarcoma and related sarcomas to 15 U.S. trial sites, including the prestigious Seattle Cancer Care Alliance and Oregon Health & Sciences University. The trial explores seclidemstat, a targeted LSD1 inhibitor, in various combinations and as a single agent. Interim data is expected in the second half of 2022. Salarius aims to improve prospects for patients with limited treatment options, with seclidemstat already receiving FDA designations for its potential.

Salarius Pharmaceuticals (NASDAQ: SLRX) has announced a collaboration with VolitionRx Limited to enhance the development of its cancer treatment, seclidemstat, utilizing Volition's Nu.Q® technology for rapid epigenetic profiling. Seclidemstat is currently in Phase 1/2 clinical trials targeting various cancers. This partnership aims to derive valuable biomarker data to assess drug activity and engagement noninvasively. Salarius is advancing its programs, including support from the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas.

Salarius Pharmaceuticals (Nasdaq: SLRX) will release its Q2 2022 financial results on August 5, 2022, followed by a conference call on August 8, 2022, at 11:00 a.m. ET. The call will discuss financial results for the quarter ending June 30, 2022, alongside recent business updates and upcoming milestones. Salarius is focused on developing cancer therapies like seclidemstat for pediatric cancers and sarcomas. The company has received key designations from the FDA and has ongoing clinical trials, bolstered by support from the National Pediatric Cancer Foundation and CPRIT.